Results 31 to 40 of about 1,844 (180)

Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials

The Egyptian Heart Journal, 2023
Background Mavacamten, an allosteric myosin inhibitor, is considered to be a promising drug for the treatment of hypertrophic cardiomyopathy (HCM). This meta-analysis aimed to explore the safety and efficacy of mavacamten in HCM patients.
Mehrdad Rabiee Rad, Ghazal Ghasempour Dabaghi, Danial Habibi   +2 more
doaj   +1 more source

Mavacamten in Symptomatic Hypertrophic Cardiomyopathy: A Paradigm Shift or Revolution? [PDF]

JACC Asia
Hung CL, Liu YW, Wu YW.
europepmc   +2 more sources

Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy

BMJ Open, 2023
Introduction Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease commonly caused by pathogenic genetic variants encoding sarcomere proteins.
Qing Zhang, Fang Wang, Yaling Han, Jing Sun, Shuyang Zhang, Wei Jin, Zhuang Tian, Ping Yang, Geng Wang, Jingmin Zhou, Peiwen Hsu   +10 more
doaj   +1 more source

Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis [PDF]

Exploration of Cardiology
Background: Myosin inhibitors have been shown to improve exercise capacity and symptoms, as well as reduce the left ventricular outflow tract (LVOT) gradient. This study explores the efficacy of mavacamten versus aficamten in hypertrophic cardiomyopathy (
Ayesha Aman, Bisma Akram, Arfa Akram, Momina Maham, Eisha Tariq, Aimen Hassan, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Malik Waleed Zeb Khan   +9 more
doaj   +1 more source

Mavacamten, uma nova terapia revolucionária na HOCM: uma revisão de literatura [PDF]

, 2021
A miocardiopatia hipertrófica (MCH) é uma das doenças cardíacas genéticas mais frequentes, sendo definida por um espessamento da parede ventricular esquerda ≥15 mm, na ausência de outras causas de sobrecarga ventricular.
Tiago Filipe Sá Lopes Ribeiro Aguiar
core  

Mavacamten: First Approval

Drugs, 2022
Mavacamten (Camzyos™) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction. In April 2022, mavacamten was approved for use in the USA in the treatment of adults with symptomatic New ...
openaire   +2 more sources

Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis

Future Science OA, 2023
Aim: This meta-analysis was performed to assess the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy. Methods & materials: A search was conducted using PubMed, Cochrane, and Scopus up to August 2022 for randomized studies ...
Areeba Memon, Muhammad Omar Larik, Zoha Khan, Maryam Urooj, Areeka Irfan, Beena Kumari, Mehak Faisal, Rida Siddiqui, Moniba Tehrim, Ishaque Hameed   +9 more
doaj   +1 more source

Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. [PDF]

BACKGROUND AND AIMS: Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term ...
Abraham, Theodore, Balaratnam, Ganesh, Barriales-Villa, Roberto, Choudhury, Lubna, Fox, Shawna, Garcia-Pavia, Pablo, Hagege, Albert, Hegde, Sheila, Jensen, Morten, Lakdawala, Neal, Masri, Ahmad, Olivotto, Iacopo, Oręziak, Artur, Owens, Anjali, Seidler, Tim, Shah, Ashish, Wang, Andrew, Wheeler, Matthew, Wojakowski, Wojciech   +18 more
core   +4 more sources

Patient-Level Artificial Intelligence–Enhanced Electrocardiography in Hypertrophic Cardiomyopathy Longitudinal Treatment and Clinical Biomarker Correlations [PDF]

, 2023
BackgroundArtificial intelligence (AI) applied to 12-lead electrocardiographs (ECGs) can detect hypertrophic cardiomyopathy (HCM).ObjectivesThe purpose of this study was to determine if AI-enhanced ECG (AI-ECG) can track longitudinal therapeutic response
Abraham, Theodore P, Abreau, Sean, Agarwal, Priyanka, Attia, Zachi I, Balasubramanyam, Aarthi, Barrios, Joshua P, Dewland, Thomas A, Edelberg, Jay M, Friedman, Paul A, Lester, Steven J, Li, Yunfan, Masri, Ahmad, Noseworthy, Peter A, Olgin, Jeffrey E, Sehnert, Amy J, Siontis, Konstantinos C, Tison, Geoffrey H, Wang, Andrew   +17 more
core   +1 more source

Effects of omecamtiv mecarbil and mavacamten in isolated human atrium [PDF]

, 2023
Heart failure is a syndrome that can result from impaired heart muscle contractions like in dilative cardiomyopathy but also from hypertrophic obstructive cardiomyopathy (HOCOM).
Abella, Lina Maria Rayo, Gergs, Ulrich, Hofmann, Britt, Höhm, Christian, Neumann, Joachim   +4 more
core   +1 more source